Vinati Organics Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - Capital expenditure (capex) plans for FY '26 are around INR 360 crores, focused on expansion, innovation, and operational efficiency. - The company is funding capex primarily through internal accruals, as there is no specific reference to raising funds via equity or debt in the call. - No mention of new debt or equity issuance for funding the ongoing ATBS expansion, VOPL capex, or other projects. - Management focuses on revenue growth, operational efficiencies, and sustained profitability rather than external fundraising.

- FY'25 capex was approx INR400 crores, focused on capacity enhancements, new products, and operational scalability including investments in Vinati Organic Products Limited (VOPL). - ATBS capacity expansion scheduled for completion by June 2025, increasing capacity by about 25-30% in Phase 1, followed by a second phase a year later. Total Brownfield capex for ATBS expansion budgeted at INR300 crores. - VOPL capex total INR500 crores; about INR250 crores done, balance pending. Products including MEHQ, Guaiacol, TAA, PTAP, Anisole, and 4-Methoxy Acetophenone will be commercialized. - FY'26 capex marked at approx INR360 crores to continue expansion, innovation, and operational efficiency. - Plans for the next leg of capex based on success of 3-4 new products currently in R&D. - Focus on vertical and horizontal integration to add products and diversify portfolio.

- Vinati Organics projects a 20% CAGR in revenue over the next three years. - Continued robust growth expected in ATBS driven by volume expansion and rising demand from oil recovery and water treatment. - Antioxidants (AO) business to see strong momentum with capacity utilization expected to increase from ~50% to 90% over two years. - Butyl phenols anticipated to grow steadily, with FY26 revenue expected between INR800-850 crores from antioxidants alone. - VOPL (Veeral Organic) subsidiary aims for ~INR100 crores revenue in FY26, ramping up product commercialization. - New products under development (anisole derivatives, 4-MAP, TAA, PTAP) to diversify portfolio and fuel growth. - Brownfield expansions for ATBS capacity planned in two phases, with phase 1 operational by June 2025. - Overall growth supported by strategic capex (~INR360 crores in FY26), innovation, and operational efficiencies.

- Vinati Organics projects a 20% CAGR in revenue over the next 3 years, driven by leadership in ATBS, steady butyl phenol performance, and strong antioxidants growth. - EBITDA margins are expected to sustain at 26%-27% over the long term (3 to 5 years), excluding other income. - Antioxidants (AO) business revenue grew 70% in FY '25 and is anticipated to continue robust growth in FY '26, supported by new product development. - ATBS segment showed 30% growth in FY '25, with continued strong demand and expected double-digit volume growth in FY '26. - Revenue from butyl phenols and antioxidants combined is expected to grow from INR600 crores in FY '25 to INR800-850 crores in FY '26. - Veeral Organic’s (VOPL) revenue is expected around INR100 crores in FY '26, with capacity utilization improving. - Continued investments in capex (~INR360 crores in FY '26) and R&D underpin future growth and operational efficiency.

- The company is currently oversold in the ATBS segment. - There is a backlog of pending orders for ATBS. - The new capacity coming in Phase 1 of the ATBS expansion is expected to be filled immediately upon commissioning due to the existing order book. - Demand remains strong, driven by the oil and gas sector and enhanced oil recovery applications. - Overall, the company has good visibility and client commitments for increased capacity.